Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 9:49 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 1,668 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Control Comparator Clear all
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Controlled Acute Hypoxia Study Comparing Pulse Oximetry to Arterial Blood Samples During Motion

NCT02247765
View directory record Official record
Conditions
Healthy, Hypoxia
Interventions
Arterial line, Motion
Device
Lead sponsor
Medtronic - MITG
Industry
Eligibility
18 Years to 50 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
2
States / cities
Boulder, Colorado
Source: ClinicalTrials.gov public record
Updated May 5, 2017 · Synced Oct 20, 2026, 9:49 AM EDT
Completed Phase 4 Interventional Results available

Comparator Study Evaluating Patient Experience And Preference Of FFNS vs. FPNS

NCT00519636
View directory record Official record
Conditions
Rhinitis, Allergic, Perennial
Interventions
FPNS, FFNS, placebo FFNS, placebo FPNS
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
28
States / cities
Birmingham, Alabama • Phoenix, Arizona • Long Beach, California + 20 more
Source: ClinicalTrials.gov public record
Updated Dec 9, 2016 · Synced Oct 20, 2026, 9:49 AM EDT
Completed Phase 4 Interventional Results available

Study of Raisins Versus Alternative Snacks in Patients With Type 2 Diabetes Mellitus

NCT01677936
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Raisins, Snacks
Other
Lead sponsor
Louisville Metabolic and Atherosclerosis Research Center
Other
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Apr 23, 2014 · Synced Oct 20, 2026, 9:49 AM EDT
Completed Not applicable Interventional Results available

Evaluation of the Efficacy and Mechanisms of a Novel Intervention for Chronic Pain Tailored to People Living With HIV

NCT03692611
View directory record Official record
Conditions
Chronic Pain
Interventions
Skills TO Manage Pain (STOMP), Comparison group
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 89 Years
Enrollment
278 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
2
States / cities
Birmingham, Alabama • Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 19, 2025 · Synced Oct 20, 2026, 9:49 AM EDT
Completed Phase 2 Interventional

Efficacy and Safety Study for Subjects With Mild-to-Moderate Alzheimer's Disease

NCT00948909
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Placebo, ABT-126, donepezil
Drug
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
55 Years to 90 Years
Enrollment
274 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
3
States / cities
Fresno, California • West Palm Beach, Florida • Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jan 31, 2013 · Synced Oct 20, 2026, 9:49 AM EDT
Completed Not applicable Interventional Results available

Diabetes Strengths Study - Pilot of Provider-delivered Strengths-based Intervention

NCT02510664
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Diabetes Strengths Study
Behavioral
Lead sponsor
Baylor College of Medicine
Other
Eligibility
12 Years to 18 Years
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 24, 2020 · Synced Oct 20, 2026, 9:49 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Antimicrobial Efficacy of ALT005 Ophthalmic Prep Solution in Healthy Volunteers

NCT01531699
View directory record Official record
Conditions
Infection Secondary to Surgical Procedure
Interventions
ALT005 Ophthalmic Prep Solution, saline control, Betadine ophthalmic prep solution
Drug · Other
Lead sponsor
Altacor Ltd.
Industry
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Neptune City, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 6, 2020 · Synced Oct 20, 2026, 9:49 AM EDT
Terminated Phase 2 Interventional Results available

Incobotulinum Toxin for the Treatment of Trigeminal Neuralgia

NCT02088632
View directory record Official record
Conditions
Trigeminal Neuralgia
Interventions
Incobotulinumtoxina, Placebo Comparator
Biological · Other
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years to 75 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 28, 2023 · Synced Oct 20, 2026, 9:49 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Safety and Tolerability of Single and Multiple Ascending Doses of GATE-101 in Normal Human Volunteers

NCT04618263
View directory record Official record
Conditions
Major Depressive Disorder, Excessive Sleepiness
Interventions
GATE-101
Drug
Lead sponsor
Syndeio Biosciences, Inc
Industry
Eligibility
18 Years to 40 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Eatontown, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 3, 2022 · Synced Oct 20, 2026, 9:49 AM EDT
Completed Phase 2 Interventional

Induction of Clinical Response Using Rifaximin in Crohn's Disease

NCT00603616
View directory record Official record
Conditions
Crohn's Disease
Interventions
Placebo Comparator, Rifaximin
Drug
Lead sponsor
Scott Lee
Other
Eligibility
18 Years to 80 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2020
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 9, 2021 · Synced Oct 20, 2026, 9:49 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Safety and Immunogenicity of CodaVax-RSV in Seropositive and Seronegative Children

NCT04919109
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
CodaVax-RSV, Normal Saline
Biological
Lead sponsor
Codagenix, Inc
Industry
Eligibility
6 Months to 5 Years
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
4
States / cities
Lincoln, Nebraska • Omaha, Nebraska • Providence, Rhode Island + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Oct 20, 2026, 9:49 AM EDT
Completed Not applicable Interventional Results available

Standardized Patient-Centered Medication Review in Home Hospice

NCT03972163
View directory record Official record
Conditions
Hospices, Poly Pharmacy, Deprescriptions, Caregivers, Palliative Care, Prescription Drug Overuse, Interdisciplinary Communication
Interventions
NIA Medication Management - Active Comparator, STOPPFrail (Screening Tool of Older Persons Prescriptions), "Discontinuing Medication Appropriately" and "Understanding the Art of Communication about Deprescribing", "Key Approaches to Support Informal Family Caregivers in Managing Medications"
Behavioral
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
65 Years to 110 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Danvers, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 21, 2025 · Synced Oct 20, 2026, 9:49 AM EDT
Completed Phase 3 Interventional

A Double-Blind, Randomized, Active- and Placebo-Controlled, Multiple-Dose Multi-Center Phase 3 Study of the Safety and Efficacy of CL-108 in the Treatment of Moderate to Severe Acute Pain and Opioid-Induced Nausea and Vomiting (OINV)

NCT02462811
View directory record Official record
Conditions
Pain, Nausea, Vomiting
Interventions
CL-108 (hydrocodone 7.5 mg, acetaminophen 325 mg, promethazine 12.5 mg), Placebo, Norco (hyrdocodone 7,5 mg, acetaminophen 325 mg)
Drug
Lead sponsor
Joseph Hazelton
Industry
Eligibility
18 Years and older
Enrollment
552 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 3, 2016 · Synced Oct 20, 2026, 9:49 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Isoflurane at Subanesthetic Concentrations - 6

NCT00000254
View directory record Official record
Conditions
Opioid-Related Disorders, Substance-Related Disorders
Interventions
40% Nitrous oxide, Sham comparator, 0.2% isoflurane, 0.4% isoflurane, 0.6% isoflurane
Drug · Other
Lead sponsor
University of Chicago
Other
Eligibility
21 Years to 34 Years · Male only
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1995
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 28, 2015 · Synced Oct 20, 2026, 9:49 AM EDT
Completed Phase 3 Interventional Results available

The CANTATA-D2 Trial (CANagliflozin Treatment And Trial Analysis - DPP-4 Inhibitor Second Comparator Trial)

NCT01137812
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Sitagliptin 100 mg, Canagliflozin 300 mg, Metformin, Sulphonylurea
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
756 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
85
States / cities
Mobile, Alabama • Goodyear, Arizona • Mesa, Arizona + 82 more
Source: ClinicalTrials.gov public record
Updated Jan 15, 2015 · Synced Oct 20, 2026, 9:49 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess CT-868 and the Relationship Between Insulin Secretory Response and Ambient Blood Glucose

NCT04973111
View directory record Official record
Conditions
Diabetes
Interventions
CT-868 as SC Injection, Placebo as SC Injection, Active Comparator as SC Injection
Drug
Lead sponsor
Carmot Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Mar 28, 2025 · Synced Oct 20, 2026, 9:49 AM EDT
Completed Not applicable Interventional Results available

Reducing Suicide Risk in Adolescents and Young Adults Via a Psychobehavioral Intervention to Regularize Daily Rhythms

NCT05317481
View directory record Official record
Conditions
Bipolar Disorder, Major Depressive Disorder, Mood Disorders, Suicide, Suicidal Ideation
Interventions
BE-SMART-DR, psychoeducational control comparator condition (CC)
Behavioral
Lead sponsor
Yale University
Other
Eligibility
16 Years to 29 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
2
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 20, 2026, 9:49 AM EDT
Withdrawn Phase 2 Interventional

Trial of Oral Hyaluronic Acid for the Prevention of Aromatase Inhibitor-Associated Arthralgias

NCT03384095
View directory record Official record
Conditions
Breast Neoplasm Female, Arthralgia
Interventions
Hyaluronic Acid (HA), Placebo
Drug · Other
Lead sponsor
Erin Newton
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
4
States / cities
Carmel, Indiana • Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jan 2, 2019 · Synced Oct 20, 2026, 9:49 AM EDT
Withdrawn Phase 4 Interventional

Ketamine vs. Placebo as Adjunctive Therapies for Severe Alcohol Withdrawal

NCT02823977
View directory record Official record
Conditions
Alcohol Withdrawal
Interventions
Ketamine, Dexmedetomidine, Normal saline
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 85 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jan 19, 2018 · Synced Oct 20, 2026, 9:49 AM EDT
Recruiting Not applicable Interventional

NT-II™ Collagen for Joint Discomfort and Function

NCT07119645
View directory record Official record
Conditions
Activity-Related Knee Discomfort, Joint Discomfort, Functional Joint Pain, Functional Knee Pain, Knee Acute and Chronic Pain
Interventions
NT-II™ (240 mg), NT-II™ 480 mg, Glucosamine/Chondroitin
Dietary Supplement
Lead sponsor
Hofseth Biocare ASA
Industry
Eligibility
20 Years to 65 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Oct 20, 2026, 9:49 AM EDT
Completed Phase 1 Interventional Results available

Study Of Two Dosing Regimens Of PF-04937319 Compared To An Approved Agent (Sitagliptin) In Patients With Type 2 Diabetes

NCT01933672
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
PF-04937319 once-daily, PF-04937319 split-dose, Sitagliptin once-daily
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 70 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
8
States / cities
DeLand, Florida • South Miami, Florida • High Point, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 27, 2016 · Synced Oct 20, 2026, 9:49 AM EDT
Completed Phase 2 Interventional Results available

Phase II Safety and Efficacy Study of Oral ORMD-0801 in Patients With Type 2 Diabetes Mellitus

NCT02496000
View directory record Official record
Conditions
Diabetes Type 2
Interventions
ORMD-0801, Placebo Comparator
Drug
Lead sponsor
Oramed, Ltd.
Industry
Eligibility
20 Years to 75 Years
Enrollment
188 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
34
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Anaheim, California + 24 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2019 · Synced Oct 20, 2026, 9:49 AM EDT
Completed Phase 2 Interventional Results available

Study of the Safety and Immune Response of a Meningococcal Vaccine Administered to Healthy Children

NCT00262028
View directory record Official record
Conditions
Prevention of Meningococcal Disease
Interventions
MenACWY-CRM Vaccine, MenACWY-PS Vaccine
Biological
Lead sponsor
Novartis Vaccines
Industry
Eligibility
12 Months to 10 Years
Enrollment
910 participants
Timeline
2005 – 2006
U.S. locations
1
States / cities
Oakland, California
Source: ClinicalTrials.gov public record
Updated Feb 11, 2016 · Synced Oct 20, 2026, 9:49 AM EDT
Terminated Not applicable Interventional Results available

Educational-Medical-Behavioral Treatment of Fecal Incontinence

NCT01717456
View directory record Official record
Conditions
Fecal Incontinence
Interventions
Education, Fiber supplements, Laxatives or anti-diarrheals, Pelvic floor muscle exercises, Tips on how to prevent fecal incontinence, Daily diary, Protective pads or garments
Other · Dietary Supplement · Drug + 1 more
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 17, 2017 · Synced Oct 20, 2026, 9:49 AM EDT